---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-288498"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:49:24.811698+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclerion appoints Regina Graul as President; CEO Peter Hecht transitions to strategic consultant

## Summary
- Regina Graul, Ph.D., appointed President effective Dec 1, 2023; CEO Peter Hecht steps down but remains strategic consultant and board member.
- Graul earns $372K base salary, bonuses up to $125K, and up to 100K restricted shares vesting over time.
- Graul previously VP at EQRx and olinciguat program lead at Cyclerion; 15+ years at Ironwood Pharmaceuticals.
- Hecht completed transitional assignment; Cyclerion to rebuild with board additions Dina Katabi and Michael Higgins.
- Company to evaluate existing assets and pursue external innovation for next phase.

## SEC filing metadata
- accession: 0001193125-23-288498
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/0001193125-23-288498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/d569286d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-288498
- JSON: https://secwatch.observer/filing/0001193125-23-288498.json
- Plain text: https://secwatch.observer/filing/0001193125-23-288498.txt

## Key facts
- Executive change
  Regina Graul was elected as President at Cyclerion Therapeutics, Inc..
  - Action: elected
  - Role: President
  source text: On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) unanimously elected Regina Graul Ph.D., as President of the Company, effective December 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/0001193125-23-288498-index.htm
- Executive change
  Peter Hecht resigned as President and Chief Executive Officer at Cyclerion Therapeutics, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: She replaces Peter Hecht, Ph.D., who resigned on November 30, 2023 as President and Chief Executive Officer to pursue his responsibilities as President of Tisento.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/0001193125-23-288498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.